{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:54:36Z","timestamp":1648752876307},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OTT"],"DOI":"10.2147\/ott.s96176","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T02:35:42Z","timestamp":1456799742000},"page":"985","source":"Crossref","is-referenced-by-count":0,"title":["A comparative study of idarubicin 12 mg\/m2 and 8 mg\/m2 combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients"],"prefix":"10.2147","author":[{"given":"Zimin","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaidi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changcheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baolin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,2]]},"container-title":["OncoTargets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=29191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:33:43Z","timestamp":1477866823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/a-comparative-study-of-idarubicin-12-mgm2-and-8-mgm2-combined-with-cyt-peer-reviewed-article-OTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/ott.s96176","relation":{},"ISSN":["1178-6930"],"issn-type":[{"value":"1178-6930","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}